USE OF FAS LIGAND TO SUPPRESS ARTHRITIS

使用 FAS 配体抑制关节炎

• 批准号: 6294448
• 负责人: DONALD BELLGRAU
• 金额: $ 10万
• 依托单位: GLOBEIMMUNE, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-07-01 至 2001-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6294448
• 关键词: CD95 molecule; antiarthritic agent; biotherapeutic agent; drug design /synthesis /production; gene delivery system; gene expression; gene mutation; gene therapy; genetic manipulation; rheumatoid arthritis

DESCRIPTION: Preliminary reports by several groups have demonstrated the potential for Fas ligand-based therapy to prevent transplant rejection, to treat autoimmune disease, to induce immunological tolerance and to treat cancer. The "Use of Fas Ligand to Suppress T-lymphocyte mediated Immune Responses" is protected by U.S. Patent No. 5,759,536, Donald Bellgrau and Richard C. Duke, Inventors. CERES Pharmaceuticals has licensed this Technology from the University of Colorado. The overall goal of this Phase I SBIR application is to develop and test in a well-established mouse model of arthritis, commercially-useful recombinant adenoviral gene therapy vectors encoding mutated versions of Fas ligand with enhanced therapeutic potential. These vectors and strategies for their production and application to treat human rheumatoid arthritis (U.S. Patents Pending) will be licensed to Pharmaceutical and/or Biotechnology companies for use in filing Investigational New Drug (IND) Applications with the FDA in anticipation of phase I clinical trails in humans. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

几个小组的初步报告已经证明了

项目成果

Fas ligand-dependent suppression of autoimmunity via recruitment and subsequent termination of activated T cells.

通过招募和随后终止活化的 T 细胞，Fas 配体依赖性自身免疫抑制。

• DOI: 10.1016/j.clim.2004.03.011
• 发表时间: 2004
• 期刊: Clinical immunology (Orlando, Fla.)
• 作者: Modiano,JaimeF;Sun,Juan;Lang,Julie;Vacano,Guido;Patterson,David;Chan,Daniel;Franzusoff,Alex;Gianani,Roberto;Meech,SandraJ;Duke,Richard;Bellgrau,Donald
• 通讯作者: Bellgrau,Donald